Figure S1. Transfection efficiency of p53-siRNAs. Data are presented as the mean ± SD (n=3). *P<0.05 and **P<0.01 vs. control. siRNA, small interfering RNA.



Figure S2. Effect of dioscin treatment (2.9, 5.8 and 11.6 $\mu$M) for 24 h on colony formation, migratory and invasive properties in A431 cells. Data are presented as the mean ± SD (n=5). $^{**}$P<0.01 vs. dioscin group. siRNA, small interfering RNA.



Figure S3. Effects of dioscin and caspase inhibitor (Z-VAD-FMK) on the expression levels of cleaved-caspase 3/9. **P<0.01 vs. dioscin group.



Table SI. Primary antibodies used in the present study.

| Antibody | Source | Dilution[a] | Company | Cat. no. |
|---|---|---|---|---|
| Rho | Rabbit | 1:1,000 | ProteinTech Group, Inc. | 10749-1-AP |
| Cdc42 | Rabbit | 1:1,000 | ProteinTech Group, Inc. | 10155-1-AP |
| GAPDH | Rabbit | 1:1,000 | ProteinTech Group, Inc. | 10494-1-AP |
| p53 | Rabbit | 1:1,000 | ProteinTech Group, Inc. | 10442-1-AP |
| Bax | Rabbit | 1:1,000 | ProteinTech Group, Inc. | 50599-2-Ig |
| Bcl-2 | Rabbit | 1:1,000 | ProteinTech Group, Inc. | 60178-1-Ig |
| Cleaved/pro caspase-3 | Rabbit | 1:1,000 | ProteinTech Group, Inc. | 19677-1-AP |
| Cleaved/pro caspase-9 | Rabbit | 1:1,000 | ProteinTech Group, Inc. | 10380-1-AP |
| Cleaved/pro PARP | Rabbit | 1:1,000 | ProteinTech Group, Inc. | 13371-1-AP |
| MMP-2 | Rabbit | 1:1,000 | ProteinTech Group, Inc. | 10373-2-AP |
| MMP-9 | Rabbit | 1:1,000 | ProteinTech Group, Inc. | 10375-2-AP |
| ATM | Rabbit | 1:500 | Wuhan Boster Biological Technology, Ltd. | bs-1370R |
| p-ATM | Rabbit | 1:500 | Wuhan Boster Biological Technology, Ltd. | bs-12545R |

[a]Dilutions used for western blotting. MMP, matrix metalloproteinase; p-ATM, phosphorylated ataxia telangiectasia-mutated; PARP, poly (ADP-ribose) polymerase.